Get Support

Learn Mode

PODD - Insulet Corp

46

$207.94

-$1.90 (-0.905%)

4/1/26, 6:17 PM

3.96/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

PODD

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$14.71B

Industry

Health Care

EPS (TTM)

$3.50

P/E (TTM)

59.52

Div & Yield

--

FCF Payout Ratio

--

P/S (TTM)

5.43

P/B

9.71

Diluted Shares

70.67M

Ex-Dividend

--

Next Earnings

04-30

Forward P/E

30.49

Payout Ratio

--

P/FCF (TTM)

42.04

FCF Yield

2.38%

Earnings Yield

1.68%

52 Week Range

Score Card

Explore Scores Tab

3.96

Good

Insulet Corp has grown revenue at 30.73% over the past year, which is strong growth. Also, it has more cash than current liabilities meaning it has enough cash to handle all its debts within the next year, if it wanted to.

Valuation Model

Key Score

4.00

Good

Management

1.00

Very Bad

Growth

1.00

Very Bad

Profitability

1.00

Very Bad

Fin. Health

5.00

Very Good

Dividends

--

--

Analyst

2.00

Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

1 new filing was in the last 7 days

Filter Form Types

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-27 09:51:32

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-12 16:06:56

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-03-04 16:06:27

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 18:52:08

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 18:49:55

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 18:48:41

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 18:47:20

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-03-03 18:45:26

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-26 16:14:16

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-26 16:12:48

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-26 16:11:41

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-26 16:10:23

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-03-25

High:

$456.75

119.7%

Avg:

$363.70

74.9%

Low:

$288.86

38.9%

(% change is relative to the current stock price: $207.94)

Analyst Recommendations

Go to Analyst Tab

4.26

Very Good

38%

Strong Buy (13)

53%

Buy (18)

6%

Hold (2)

3%

Sell (1)

0%

Strong Sell (0)

About

Website
https://www.omnipod.com
Address
100 Nagog Park, Acton MASSACHUSETTS, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1145197

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts and currently employs 5,400 full-time employees. The company went IPO on 2007-05-15. The company is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. The company also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.

IPO Date

2007-05-15

Industry

Health Care

Total Employees

5,400

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Health Care Equipment & Supplies

GICS Sub

Health Care Equipment

GICS Sector

Health Care

GICS Group

Health Care Equipment & Services